Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Top Cited Papers
- 1 May 2018
- journal article
- review article
- Published by Elsevier in Antiviral Research
- Vol. 153, 85-94
Abstract
No abstract availableKeywords
Funding Information
- Belgian Federal Science Policy Office
- KU Leuven (PDM/17/178)
This publication has 67 references indexed in Scilit:
- Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replicationArchives of Virology, 2017
- Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravirAntiviral Research, 2016
- Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever virusesAntiviral Research, 2016
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy TrialsClinical Pharmacokinetics, 2016
- Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic feverAntiviral Research, 2015
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatmentAntiviral Research, 2014
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse modelAntiviral Research, 2014
- Effect of T-705 treatment on western equine encephalitis in a mouse modelAntiviral Research, 2009
- Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsAntiviral Research, 2008